Seer, Inc. Announces Returning of its President and Chief Operating Officer, Omead Ostadan from Previously Announced 3 Month Leave of Absence
February 18, 2022 at 04:06 pm
Share
On February 18, 2022, Seer, Inc. announced that its President and Chief Operating Officer, Omead Ostadan, was returning from a previously announced 3 month leave of absence. Mr. Ostadan will initially return on a part-time basis as the company's President beginning on February 28, 2022 and his part-time status is expected to last approximately 10 months for ongoing personal reasons.
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.
SEER, INC. 
